<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02799147</url>
  </required_header>
  <id_info>
    <org_study_id>05/16-n</org_study_id>
    <nct_id>NCT02799147</nct_id>
  </id_info>
  <brief_title>GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia</brief_title>
  <official_title>Dose-escalation Study of Graft-versus-host Disease Prophylaxis With High-dose Post-transplantation Bendamustine in Patients With Refractory Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Petersburg State Pavlov Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Petersburg State Pavlov Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several groups have demonstrated very low incidence of acute and chronic graft-versus-host
      disease (GVHD) with post-transplantation cyclophosphamide (PTCy) in haploidentical, unrelated
      and related allogeneic stem cell transplantation (SCT). Nonetheless for majority of the
      grafts, except for 10/10 HLA-matched bone marrow, with this type of prophylaxis require
      concomitant administration of calcineurin inhibitors±MMF, which delays immune reconstitution
      and development of graft-versus-leukemia (GVL) effect. So, despite reduction of
      transplant-related mortality, use of PTCy doesn't lead to the reduction of relapse incidence.
      This is particularly important for relapsed or refractory acute leukemia patients, where,
      despite all efforts to intensify conditioning regimens, relapses after SCT occur in more than
      50% of patients, and long-term survival rarely exceeds 10-20%. In preclinical model of
      haploidentical SCT the substitution of post-transplantation cyclophosphamide with
      bendamustine, led to comparable GVHD control, but significantly augmented GVL effect. To test
      this hypothesis and improve the outcome of allogeneic SCT in refractory acute leukemia
      patients we initiated a pilot trial with high-dose post-transplantation bendamustine for GVHD
      prophylaxis. The selection of doses is based on the previous dose-escalation studies.
      Additional immunosuppression could be added for mismatched grafts.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Engraftment rate</measure>
    <time_frame>60 days</time_frame>
    <description>Engraftment is defined as the first of 3 consecutive days with an ANC&gt;500 per μl and WBC&gt;1000 per μl. Platelet engraftment is not mandatory for the endpoint.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse rate analysis</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality analysis</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute GVHD, grades II-IV</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD, moderate and severe (NIH criteria)</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival analysis</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival analysis</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (NCI CTCAE 4.03)</measure>
    <time_frame>100 days</time_frame>
    <description>Toxicity parameters based on NCI CTCAE 4.03 grades: hepatotoxicity (liver function tests), nephrotoxicity (creatinine), neurotoxicity (attending physician assessment), mucositis (attending physician assessment), hemorrhagic cystitis (attending physician assessment), cardiotoxicity (ECG, echocardiography). Additional toxicity parameters: incidence and severity of veno-occlusive disease, incidence of transplant-associated microangiopathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infectious complications, including analysis of severe bacterial, fungal and viral infections incidence</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Leukemia, Acute Lymphoblastic</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Mixed-Lineage Acute Leukemias</condition>
  <arm_group>
    <arm_group_label>280 mg/m2 bendamustine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -3: Busulfan 1 mg/kg po qid №14 Day 0: Infusion of unmanipulated graft Day +3 and +4: Bendamustine 140 mg/m2/day iv.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg/m2 bendamustine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -3: Busulfan 1 mg/kg po qid №14 Day 0: Infusion of unmanipulated graft Day +3 and +4: Bendamustine 100 mg/m2/day iv</description>
  </arm_group>
  <arm_group>
    <arm_group_label>210 mg/m2 bendamustine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -3: Busulfan 1 mg/kg po qid №14 Day 0: Infusion of unmanipulated graft Day +3, +4, +5: Bendamustine 70 mg/m2/day iv.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic stem cell transplantation</intervention_name>
    <arm_group_label>280 mg/m2 bendamustine</arm_group_label>
    <arm_group_label>200 mg/m2 bendamustine</arm_group_label>
    <arm_group_label>210 mg/m2 bendamustine</arm_group_label>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine monophosphate</intervention_name>
    <arm_group_label>280 mg/m2 bendamustine</arm_group_label>
    <arm_group_label>200 mg/m2 bendamustine</arm_group_label>
    <arm_group_label>210 mg/m2 bendamustine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <arm_group_label>280 mg/m2 bendamustine</arm_group_label>
    <arm_group_label>200 mg/m2 bendamustine</arm_group_label>
    <arm_group_label>210 mg/m2 bendamustine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <arm_group_label>280 mg/m2 bendamustine</arm_group_label>
    <arm_group_label>200 mg/m2 bendamustine</arm_group_label>
    <arm_group_label>210 mg/m2 bendamustine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Diagnosis: Acute Myeloblastic Leukemia Acute Lymphoblastic Leukemia Mixed-Lineage Acute
        Leukemias

          -  Disease, refractory to at list one course of induction chemotherapy or immunotherapy

          -  More than 5% clonal blasts in the bone marrow or peripheral blood at the time of
             inclusion

          -  Signed informed consent

          -  Matched related, 8-10/10 HLA-matched unrelated or haploidentical donor available. The
             HLA typing is performed by the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1,
             and HLA-DQB1.

          -  No second tumors

          -  No severe concurrent illness

          -  No previous autologous or allogeneic stem cell transplantations

        Exclusion Criteria:

          -  Karnofsky index &lt;70%

          -  Moderate or severe cardiac dysfunction, left ventricular ejection fraction &lt;50%

          -  Moderate or severe decrease in pulmonary function, FEV1 &lt;70% or DLCO&lt;70% of predicted

          -  Respiratory distress &gt;grade I

          -  Severe organ dysfunction: AST or ALT &gt;5 upper normal limits, bilirubin &gt;1.5 upper
             normal limits, creatinine &gt;1.5 upper normal limits

          -  Creatinine clearance &lt; 60 mL/min

          -  Uncontrolled bacterial or fungal infection at the time of enrollment, defined by CRP
             level &gt;70 mg/L or positive procalcitonin in patient with adequate empirical
             antibacterial and antifungal therapy.

          -  Requirement for vasopressor support at the time of enrollment

          -  Pregnancy

          -  Somatic or psychiatric disorder making the patient unable to sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris V. Afanasyev, Professor</last_name>
    <role>Study Director</role>
    <affiliation>St. Petersburg State Pavlov Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boris V. Afanasyev, Professor</last_name>
    <phone>+78122334551</phone>
    <email>coordinatorbmt@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ivan S. Moiseev, PhD</last_name>
    <phone>+79217961951</phone>
    <email>moisiv@mail.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Pavlov State Medical University of St. Petersburg</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan S. Moiseev, PhD</last_name>
      <phone>+79217961951</phone>
      <email>moisiv@mail.ru</email>
    </contact>
    <contact_backup>
      <last_name>Olga A. Slesarchuk, PhD</last_name>
      <phone>+79111910003</phone>
      <email>olga.slesarchuk@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Olga V. Pirogova, M.S.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <reference>
    <citation>Stokes J, Hoffman EA, Zeng Y, Larmonier N, Katsanis E. Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation. Br J Haematol. 2016 Jul;174(1):102-16. doi: 10.1111/bjh.14034. Epub 2016 Mar 31.</citation>
    <PMID>27030315</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2016</study_first_submitted>
  <study_first_submitted_qc>June 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allogeneic Transplantation</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>Leukemia, Acute Lymphoblastic</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Mixed-Lineage Acute Leukemias</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Immunosuppressive Agents</keyword>
  <keyword>Myeloablative Agonists</keyword>
  <keyword>Busulfan</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Antineoplastic Agents, Alkylating</keyword>
  <keyword>Bendamustine Hydrochloride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Biphenotypic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Antineoplastic Agents, Alkylating</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Consultations are ongoing about how IPD initiative fits the local law &quot;About personal data 152-fz&quot;.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

